This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Haemophilia A

Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Sponsored by Novo Nordisk A/S

About this trial

Last updated 3 years ago

Study ID

NN7088-4484

Status

Enrolling by invitation

Type

Observational

Placebo

No

Accepting

18-75 Years
All
All
All

Trial Timing

Ended 3 months ago

What is this trial about?

The purpose of this study is to assess the safety and effectiveness of Esperoct® for long-term routine use in patients with Haemophilia A. Participants will get Esperoct® as prescribed by their doctor. The study will last for about 2 years for each participant.

What are the participation requirements?

Yes

Inclusion Criteria

- Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).

- The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

- Diagnosis of haemophilia A in males or females, no age limitation.

- New patients who have not previously been exposed to Esperoct®.

No

Exclusion Criteria

- Previous participation in this study. Participation is defined as having given informed consent in this study.

- Known or suspected hypersensitivity to study product or related products.

- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Locations

Location

Status